Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 11
Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Galapagos NV, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
ProQR Therapeutics and Galapagos Enter into Research Agreeement 14
Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 15
Pharnext Enters into Research Agreement with Galapagos 16
Gilead Sciences Enters into Co-Development Agreement with Galapagos 17
Calchan Enters into Research Partnership with Galapagos 18
Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 19
AbbVie Expands its Agreement with Galapagos 20
Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 22
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 23
Licensing Agreements 25
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 25
Vlaams Instituut, Centre for Drug Design and Galapagos Enter into License Agreement 27
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 28
ThromboGenics Enters into Licensing Agreement with Galapagos 29
Galapagos Enters into Licensing Agreement with HUB foundation 30
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 31
Equity Offering 32
Galapagos Raises USD1.5 Million in Private Placement of Shares up on Exercise of Warrants 32
Galapagos Raises USD4.8 Million in Private Placement of Shares up on Exercise of Warrants 33
Galapagos Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 34
Galapagos Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 35
Galapagos Raises USD0.7 Million in Private Placement of Shares up on Exercise of Warrants 36
Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 37
Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 39
Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 40
Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 41
Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 42
Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 43
Galapagos Raises USD425 Million in Private Placement of Shares 44
Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 45
Galapagos Raises USD1.3 Million in Private Placement of Shares upon Exercise of Warrants 46
Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 47
Galapagos Raises USD74.5 Million in Private Placement of Shares 48
Galapagos Raises USD240 Million in Public Offering of Shares 50
Galapagos to Raise Funds through Private Placement 52
Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 53
Galapagos Completes Private Placement Of Shares For US$2.2 Million Upon Exercise Of Warrants 54
Galapagos Completes Private Placement Of Shares For US$70 Million 55
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 56
Galapagos Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 57
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 58
Asset Transactions 59
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 59
Acquisition 60
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Galapagos Acquires Cangenix, Drug Discovery Company, For Up To US$2.3 Million 63
Galapagos NV – Key Competitors 64
Galapagos NV – Key Employees 65
Galapagos NV – Locations And Subsidiaries 66
Head Office 66
Other Locations & Subsidiaries 66
Recent Developments 67
Financial Announcements 67
Aug 02, 2018: Productive first half-year at Galapagos 67
Apr 25, 2018: Galapagos reports first quarter 2018 results 68
Oct 26, 2017: Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline 69
Jul 27, 2017: Solid financials support R&D progress 70
Jul 27, 2017: Galapagos: Solid financials support R&D progress 71
Apr 27, 2017: Galapagos reports first quarter 2017 results 72
Feb 23, 2017: Galapagos reports strong financial results and newsflow-rich pipeline 73
Corporate Communications 75
Jan 17, 2017: Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer 75
Product News 76
05/15/2017: Seven abstracts on filgotinib accepted by EULAR 2017 76
Clinical Trials 77
May 01, 2018: Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients 77
Feb 17, 2018: Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego 78
Sep 27, 2017: MorphoSys and Galapagos Report First Promising Signs of Clinical Activity in a Phase 1 Study With IL-17C-Antibody MOR106 in Atopic Dermatitis Patients 80
Jul 05, 2017: Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis 82
May 07, 2017: Galapagos presents three posters on filgotinib in Crohn’s disease at DDW 2017 83
Apr 29, 2017: Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI 84
Apr 25, 2017: Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus 85
Apr 05, 2017: Galapagos doses first psoriatic arthritis patient with filgotinib 86
Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib 87
Mar 22, 2017: Galapagos initiates Phase 1 study with novel CF potentiator GLPG3067 88
Mar 10, 2017: New Phase 2 studies with filgotinib in small bowel and fistulizing Crohn’s disease 89
Feb 23, 2017: Galapagos doses first healthy volunteer with CF combo GLPG2222 and GLPG2451 90
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91
Galapagos NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 11
Galapagos NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
ProQR Therapeutics and Galapagos Enter into Research Agreeement 14
Galapagos Exercises Co-Promotion Option with Gilead Sciences for filgotinib 15
Pharnext Enters into Research Agreement with Galapagos 16
Gilead Sciences Enters into Co-Development Agreement with Galapagos 17
Calchan Enters into Research Partnership with Galapagos 18
Mimetas And Galapagos Enter Into Agreement To Develop Human Disease Models On-A-Chip 19
AbbVie Expands its Agreement with Galapagos 20
Edinburgh Cancer Research UK Centre And Edinburgh BioQuarter Enter Into Co-Development Agreement With Galapagos 22
Abbott Enters Into Co-Development Agreement With Galapagos For Autoimmune Disease Drug 23
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 25
Vlaams Instituut, Centre for Drug Design and Galapagos Enter into License Agreement 27
Les Laboratoires Servier Exercises Option for Licensing Agreement with Galapagos 28
ThromboGenics Enters into Licensing Agreement with Galapagos 29
Galapagos Enters into Licensing Agreement with HUB foundation 30
GlaxoSmithKline Exercises Option To License GLPG0778 And GLPG0555 From Galapagos 31
Galapagos Raises USD1.5 Million in Private Placement of Shares up on Exercise of Warrants 32
Galapagos Raises USD4.8 Million in Private Placement of Shares up on Exercise of Warrants 33
Galapagos Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 34
Galapagos Raises USD0.3 Million in Private Placement of Shares upon Exercise of Warrants 35
Galapagos Raises USD0.7 Million in Private Placement of Shares up on Exercise of Warrants 36
Galapagos Raises USD388 Million in Public Offering of American Depositary Shares 37
Galapagos Raises USD4.3 Million in Private Placement of Shares upon Exercise of Warrants 39
Galapagos Raises Funds through Private Placement of Shares upon Exercise of Warrants 40
Galapagos Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 41
Galapagos Raises USD1.7 Million in Private Placement of Shares upon Exercise of Warrants 42
Galapagos Raises USD1.6 Million in Private Placement of Shares upon Exercise of Warrants 43
Galapagos Raises USD425 Million in Private Placement of Shares 44
Galapagos Raises USD0.6 Million in Private Placement of Shares upon Exercise of Warrants 45
Galapagos Raises USD1.3 Million in Private Placement of Shares upon Exercise of Warrants 46
Galapagos Raises USD5 Million in Private Placement of Shares upon Exercise of Warrants 47
Galapagos Raises USD74.5 Million in Private Placement of Shares 48
Galapagos Raises USD240 Million in Public Offering of Shares 50
Galapagos to Raise Funds through Private Placement 52
Galapagos Raises USD6.4 Million in Private Placement upon Exercise of Warrants 53
Galapagos Completes Private Placement Of Shares For US$2.2 Million Upon Exercise Of Warrants 54
Galapagos Completes Private Placement Of Shares For US$70 Million 55
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 56
Galapagos Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 57
Galapagos Completes Private Placement Of Shares For US$1.5 Million Upon Exercise Of Warrants 58
Dart Therapeutics Acquires Rights to SARM Drug Candidate from Galapagos 59
Johnson & Johnson Sells its 5.1% Interest in Galapagos for USD95.7 Million 60
Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61
Galapagos Acquires Cangenix, Drug Discovery Company, For Up To US$2.3 Million 63
Galapagos NV, Key Competitors 64
Galapagos NV, Key Employees 65
Galapagos NV, Subsidiaries 66
List of Figures
Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Galapagos NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Galapagos NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Galapagos NV, Medical Devices Deals, 2012 to YTD 2018 11
